Endpoint
Oesophageal cancer incidence
CAT:outcome/oesophageal-cancer-incidencereported in risk ratio2 findings from 2 compounds
What moved it
How to read these marks2 findings · 2 compounds · 1 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| α-tocopherol | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| spironolactone | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Reported to move it
1 finding
α-tocopherol — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“In a comprehensive analysis, we found that dietary vitamin E intake was inversely associated with the esophageal cancer risk (OR = 0.47, 95% CI: 0.36–0.60) with significant heterogeneity (I2 = 67.5%; p < 0.001) (, Table 2).”
Quoted verbatim from Association between Dietary Vitamin E Intake and Esophageal Cancer Risk: An Updated Meta-Analysis.. - Study
- meta-analysis
- Population
- Adults in 14 studies (1 cohort, 11 of the 12 articles case-control) comparing the highest versus lowest category of dietary vitamin E intake from food frequency questionnaires; all esophageal cancer subtypes pooled
Effect 0.47 odds ratio, 95% CI 0.36 to 0.6
Association between Dietary Vitamin E Intake and Esophageal Cancer Risk: An Updated Meta-Analysis.2018PMID:29933640Permalink
Measured, no effect detected
1 finding
spironolactone — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“There was no statistically significant association between spironolactone use and risk of ovarian cancer (RR, 1.52; 95% CI, 0.84-2.20; certainty of evidence very low), bladder cancer (RR, 0.89; 95% CI, 0.71-1.07; certainty of evidence very low), kidney cancer (RR, 0.96; 95% CI, 0.85-1.07; certainty of evidence low), gastric cancer (RR, 1.02; 95% CI, 0.80-1.24; certainty of evidence low), or esophageal cancer (RR, 1.09; 95% CI, 0.91-1.27; certainty of evidence low).”
Quoted verbatim from Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.. - Study
- meta-analysis
- Population
- Men and women aged 18 years and older ever exposed to spironolactone, pooled from seven observational studies
Effect 1.09 risk ratio, 95% CI 0.91 to 1.27
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.2022PMID:35138351Permalink
How it is measured
Incident oesophageal cancer diagnoses over the follow-up the source states.
Sources cited
2 papers
- Subject
- oesophageal cancer incidence
- Findings
- 2
- Papers
- 2